← Leaderboards
Erik Allen Jensen
Children'S Hosp Of Philadelphia
$3,441,542
Attributed
$4,433,695
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,433,695 · 4
By mechanism
R01$2,435,958 · 1
K23$818,994 · 1
R34$792,000 · 1
R21$386,743 · 1
Top collaborators
- Krithika Lingappan2 shared
- Kevin James Downes1 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Steven J Skates$12,789,005
- Frederic D Bushman$38,686,561
- Diva Del Carmen De Leon$8,108,270
- Jayanthi S Lea$1,091,693
- Bo Li$3,001,562
Others in their field
Other Emerging Leaders on “Evidence Base”
- Chanza Baytop · Westat, Inc.$271,217,917
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Susan M Landau · University Of California Berkeley$47,252,026
- Abraham Aizer Brody · New York University School Of Medicine$44,858,181
- Greg Yothers · University Of Chicago$29,898,807
- John H Alexander · Duke University$22,057,000
Research focus
Evidence BasePregnancyLungInfantChronicCostPremature InfantPathologicCognitionPremature BirthRespiratoryBronchopulmonary DysplasiaChildhoodChildAffectNeurodevelopmental ImpairmentMicrobialCardiopulmonaryLifeChronic Lung DiseaseCessation Of LifeCytokineDisabilityHeterogeneity
Grant awards (12)
Multidimensional phenotype classification in grade 3 BPD$838,922
R01 · FY2025 · HL
Multidimensional phenotype classification in grade 3 BPD$837,385
R01 · FY2024 · HL
Pilot trial comparing transpyloric to gastric feeding in very preterm infants with bronchopulmonary dysplasia$386,743
R21 · FY2024 · HD · contact PI
Multidimensional phenotype classification in grade 3 BPD$759,651
R01 · FY2023 · HL · contact PI
Phase 1 trial of inhaled tobramycin in very preterm infants with bronchopulmonary dysplasia$308,000
R34 · FY2023 · HL
Phase 1 trial of inhaled tobramycin in very preterm infants with bronchopulmonary dysplasia$220,000
R34 · FY2022 · HL · contact PI
Microbiome of the Airway and the Risk for Bronchopulmonary Dysplasia in the Lungs of Extreme Preterms: The MARBLE Study$163,309
K23 · FY2022 · HL · contact PI
Phase 1 trial of inhaled tobramycin in very preterm infants with bronchopulmonary dysplasia$264,000
R34 · FY2021 · HL · contact PI
Microbiome of the Airway and the Risk for Bronchopulmonary Dysplasia in the Lungs of Extreme Preterms: The MARBLE Study$163,310
K23 · FY2021 · HL · contact PI
Microbiome of the Airway and the Risk for Bronchopulmonary Dysplasia in the Lungs of Extreme Preterms: The MARBLE Study$163,782
K23 · FY2020 · HL · contact PI
Microbiome of the Airway and the Risk for Bronchopulmonary Dysplasia in the Lungs of Extreme Preterms: The MARBLE Study$163,785
K23 · FY2019 · HL · contact PI
Microbiome of the Airway and the Risk for Bronchopulmonary Dysplasia in the Lungs of Extreme Preterms: The MARBLE Study$164,808
K23 · FY2018 · HL · contact PI